E-cigarette Nicotine Delivery: Data and Learnings from Pharmacokinetic Studies

Area of Science:

• Pharmacology
• Tobacco Harm Reduction
• Nicotine Pharmacokinetics

Background:

• E-cigarettes offer potential for tobacco harm reduction due to lower toxicant levels than traditional cigarettes.
• E-cigarettes may assist with smoking behavior changes, including reduction and cessation.

Purpose of the Study:

• To compare blood nicotine levels between e-cigarette use and cigarette smoking.
• To investigate nicotine delivery differences in non-accustomed smokers versus accustomed e-cigarette users.

Main Methods:

• Two studies were conducted: Study 1 (non-accustomed smokers) and Study 2 (accustomed e-cigarette users).
• Participants' blood nicotine levels (Cmax) were measured during controlled puffing periods using either a cigarette or a closed modular system e-cigarette.

Main Results:

• In Study 1, e-cigarettes delivered significantly lower Cmax nicotine (2.5 ng/mL) compared to cigarettes (13.4 ng/mL) over a 5-minute period.
• In Study 2, Cmax nicotine levels were similar between e-cigarettes (7.8 ng/mL) and cigarettes (7.2 ng/mL) during ad libitum use.

Conclusions:

• Nicotine delivery from e-cigarettes is heterogeneous, varying by product and user experience (accustomed vs. non-accustomed).
• These delivery differences are crucial for understanding the behavioral impact of e-cigarettes on smoking reduction and cessation.
• Future pharmacokinetic studies of e-cigarettes should account for user cohort and product variability.